Biohackers in the Epstein Files, Generic GLP-1s, Continuous Ketone Monitors, and more... : 1411

This episode covers: 

• Longevity Influence In The Epstein Files 

A new DOJ document release tied to the Epstein investigation pulled physician and longevity influencer Peter Attia into the spotlight, after reports showed he appeared in the files more than 1,800 times and CBS News pulled a planned rebroadcast of its 60 Minutes profile. Dave breaks down why this story matters beyond headlines: longevity relies heavily on trust, authority, and influence, and when those foundations are shaken it exposes how fragile centralized expertise can be. He explains how biohackers can protect themselves by diversifying information sources, understanding mechanisms instead of personalities, and building health strategies that don’t collapse when one voice disappears. 

• Source: https://variety.com/2026/tv/news/cbs-news-pulls-peter-attia-60-minutes-segment-epstein-1236650930/ 

• Age-Reversal Gene Therapy Enters Human Trials 

Life Biosciences received FDA authorization to begin the first U.S. human trial of a partial epigenetic reprogramming gene therapy in the eye, using three Yamanaka factors to restore function in damaged retinal cells. Dave explains why eyes are the ideal first testing ground, what partial reprogramming actually means, and why this marks a shift from longevity theory into real clinical testing. He also clarifies what success would and would not mean for whole-body rejuvenation, and how to separate legitimate gene-therapy advances from consumer products that only claim to affect biological age. 

• Source: https://fortune.com/2026/01/30/billionaires-longevity-aging-fda-human-clinical-trial-life-biosciences/ 

• Continuous Ketone Monitoring Moves Toward Reality 

Wearable continuous ketone monitoring is advancing beyond finger-stick meters, with companies adapting the same model that made continuous glucose monitors mainstream. Dave explains why this is a major upgrade for metabolic flexibility, keto diets, fasting, and diabetes risk management. He breaks down how real-time ketone data can reveal patterns missed by spot checks, and why biohackers should think ahead about data ownership, integration, and how ketone signals interact with glucose, sleep, stress, and training. 

• Source: https://finance.yahoo.com/news/global-market-blood-ketone-meters-140900796.html 

• Injectable, Wireless Brain Implants Without Surgery 

Researchers are developing nano-scale, wireless brain implants capable of crossing the blood-brain barrier without open surgery, opening the door to a new class of neural interfaces. Dave connects this research to other circuit-level interventions like sound and light stimulation, explaining the broader shift from targeting molecules to tuning brain networks. He also addresses the ethical risks, including consent, privacy, and neuro-surveillance, and why biohackers should track this space early rather than after it becomes normalized. 

• Source: https://longevity.technology/unlocked/longevity-news-roundup-week-5-2026/ 

• Generic GLP-1 Drugs Could Reshape Global Metabolic Health 

India’s Sun Pharma is preparing to launch a generic semaglutide-style injectable as patent protections expire, signaling a major price drop and access expansion for GLP-1 drugs. Dave explains why this could transform obesity, diabetes, and cardiovascular disease management worldwide, while also highlighting the risks of muscle loss and metabolic weakness if these drugs are used without proper training and nutrition. He shares how biohackers should think about stacking GLP-1s intelligently, with resistance training, protein intake, and long-term maintenance strategies. 

• Source: https://longevity.technology/unlocked/longevity-news-roundup-week-5-2026/ 

All source links are provided for direct access to the original reporting and research. 

This episode is designed for biohackers, longevity seekers, and high-performance listeners who want clear thinki